Alpha Cognition (NASDAQ:ACOG – Get Free Report) posted its earnings results on Monday. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.03), Zacks reports.
Alpha Cognition Price Performance
Shares of Alpha Cognition stock opened at $5.06 on Tuesday. The stock has a market cap of $81.06 million, a P/E ratio of -1.98 and a beta of 2.50. Alpha Cognition has a 1 year low of $4.66 and a 1 year high of $7.00. The stock’s fifty day simple moving average is $5.83.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Alpha Cognition in a research report on Monday. Raymond James raised Alpha Cognition to a “moderate buy” rating in a research report on Tuesday, March 25th.
About Alpha Cognition
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Featured Stories
- Five stocks we like better than Alpha Cognition
- 3 Healthcare Dividend Stocks to Buy
- Is Now the Right Time to Invest in a Natural Gas ETF?
- 10 Best Airline Stocks to Buy
- Amprius Market Gets Amped Up on Growth Outlook
- The 3 Best Blue-Chip Stocks to Buy Now
- ETFs With the Best Returns of 2025: Gold and Silver Miners on Top
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
